AU2014244053B2 - Treatment of a diastolic cardiac dysfunction with a TRPV2 receptor agonist - Google Patents

Treatment of a diastolic cardiac dysfunction with a TRPV2 receptor agonist Download PDF

Info

Publication number
AU2014244053B2
AU2014244053B2 AU2014244053A AU2014244053A AU2014244053B2 AU 2014244053 B2 AU2014244053 B2 AU 2014244053B2 AU 2014244053 A AU2014244053 A AU 2014244053A AU 2014244053 A AU2014244053 A AU 2014244053A AU 2014244053 B2 AU2014244053 B2 AU 2014244053B2
Authority
AU
Australia
Prior art keywords
probenecid
trpv2
receptor agonist
subject
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014244053A
Other languages
English (en)
Other versions
AU2014244053A1 (en
Inventor
Keith W. Jones
Jack RUBINSTEIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of AU2014244053A1 publication Critical patent/AU2014244053A1/en
Application granted granted Critical
Publication of AU2014244053B2 publication Critical patent/AU2014244053B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2014244053A 2013-03-13 2014-03-13 Treatment of a diastolic cardiac dysfunction with a TRPV2 receptor agonist Active AU2014244053B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361778826P 2013-03-13 2013-03-13
US61/778,826 2013-03-13
PCT/US2014/025930 WO2014160153A1 (en) 2013-03-13 2014-03-13 Treatment of a diastolic cardiac dysfunction with a trpv2 receptor agonist

Publications (2)

Publication Number Publication Date
AU2014244053A1 AU2014244053A1 (en) 2015-09-24
AU2014244053B2 true AU2014244053B2 (en) 2018-08-30

Family

ID=50680137

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014244053A Active AU2014244053B2 (en) 2013-03-13 2014-03-13 Treatment of a diastolic cardiac dysfunction with a TRPV2 receptor agonist

Country Status (7)

Country Link
US (1) US10583103B2 (enExample)
EP (1) EP2968238A1 (enExample)
JP (3) JP2016512564A (enExample)
AU (1) AU2014244053B2 (enExample)
CA (1) CA2904671C (enExample)
MX (1) MX376077B (enExample)
WO (1) WO2014160153A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US9828603B2 (en) 2012-08-13 2017-11-28 Cedars Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
US11357799B2 (en) 2014-10-03 2022-06-14 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
US11759482B2 (en) 2017-04-19 2023-09-19 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
US20210085801A1 (en) * 2017-12-12 2021-03-25 Cardiol Therapeutics Inc. Amphiphilic block copolymers, micelles, and methods for treating or preventing heart failure
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
AU2020370872A1 (en) * 2019-10-25 2022-04-21 Cardiol Therapeutics Inc. Cannabidiol compositions for use in treating heart conditions
AU2021223191A1 (en) * 2020-02-19 2022-10-13 MERCHANT, Shreema Compositions and therapeutic uses of cannabidiol
KR20210150011A (ko) * 2020-06-03 2021-12-10 주식회사 삼오파마켐 프로베네시드 및 아르기닌의 아미드 유도체, 이를 포함하는 약제학적 조성물 및 이의 제조 방법
CN113861633B (zh) * 2021-10-14 2022-12-20 武汉工程大学 一种p-n-b阻燃pbs塑料及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130046021A1 (en) * 2011-08-12 2013-02-21 University Of Cincinnati Methods of treating cardiomyopathy, systolic cardiac dysfunction and the symptoms of congestive heart failure with probenecid

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3524917A (en) 1969-02-10 1970-08-18 Merck & Co Inc Tablets of magnesium probenecid tetrahydrate
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPH01211582A (ja) 1988-02-16 1989-08-24 Tanabe Seiyaku Co Ltd ベンゾジオキソール誘導体
ATE162075T1 (de) 1991-09-09 1998-01-15 Warner Lambert Co Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
US20030212123A1 (en) 1997-05-05 2003-11-13 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
US6221856B1 (en) 1999-02-03 2001-04-24 Inologic, Inc. Inositol derivatives for inhibiting superoxide anion production
DE60137635D1 (de) 2000-06-28 2009-03-26 Merck & Co Inc Verwendung von allopurinol zur behandlung von bluthochdruck
AU2001227030A1 (en) 2000-11-22 2002-06-03 Lupin Laboratories Limited Pharmaceutical composition for controlled release of an active ingredient
DE10064997A1 (de) 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
US20080051428A1 (en) 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
US7351692B2 (en) 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
EP1577317A4 (en) 2002-12-25 2007-05-09 Kissei Pharmaceutical NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, MEDICINAL COMPOSITIONS COMPRISING SAID DERIVATIVES AND MEDICAL USE OF SAID DERIVATIVES
EP1666880B1 (en) 2003-09-11 2008-08-20 Takeda Pharmaceutical Company Limited Screening method
DE10352511A1 (de) 2003-11-07 2005-06-16 Ernst-Moritz-Arndt-Universität Greifswald Verwendung von MRP4-Inhibitoren zur Behandlung und/oder Prophylaxe kardiovaskulärer Erkrankungen
JP2007511528A (ja) 2003-11-13 2007-05-10 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 心肥大および心不全の処置としてのｔｒｐチャネル阻害方法
KR20060124712A (ko) 2004-02-20 2006-12-05 노파르티스 아게 신경퇴행 및 인지 장애를 치료하기 위한 ｄｐｐ ⅳ 억제제
CA2557766C (en) 2004-03-04 2013-02-05 Kissei Pharmaceutical Co., Ltd. Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
CA2560005A1 (en) 2004-03-31 2005-10-13 Kissei Pharmaceutical Co., Ltd. Phenol derivative, medicinal composition containing the same, and medicinal use thereof
EP2068879A2 (en) 2006-05-02 2009-06-17 Medical Technology Acceleration Program, Inc. Pyrroloquinoline quinone drugs and methods of use thereof
JP2009149534A (ja) 2007-12-18 2009-07-09 Japan Health Science Foundation Ｔｒｐｖ２阻害剤，疾患の予防又は治療剤，薬剤探索用リード化合物，及び薬剤探索方法
KR100951656B1 (ko) 2008-02-25 2010-04-07 고려대학교 산학협력단 프로베네시드를 포함하는 ｔｒｐｖ２ 활성제
EP2317995B1 (en) 2008-07-17 2016-12-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhbitors of mrp4 and agents stimulating mrp4 activity for the treatment of cardiac disorders
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8980223B2 (en) 2009-05-07 2015-03-17 University Of Cincinnati Methods of preventing ischemic injury using peripheral nociceptive stimulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130046021A1 (en) * 2011-08-12 2013-02-21 University Of Cincinnati Methods of treating cardiomyopathy, systolic cardiac dysfunction and the symptoms of congestive heart failure with probenecid

Also Published As

Publication number Publication date
MX376077B (es) 2025-03-07
JP2024009140A (ja) 2024-01-19
JP2021042248A (ja) 2021-03-18
CA2904671A1 (en) 2014-10-02
EP2968238A1 (en) 2016-01-20
US10583103B2 (en) 2020-03-10
MX2015012547A (es) 2016-02-10
AU2014244053A1 (en) 2015-09-24
CA2904671C (en) 2022-08-30
WO2014160153A1 (en) 2014-10-02
US20160008305A1 (en) 2016-01-14
JP2016512564A (ja) 2016-04-28

Similar Documents

Publication Publication Date Title
AU2014244053B2 (en) Treatment of a diastolic cardiac dysfunction with a TRPV2 receptor agonist
Ma et al. Piperine attenuates pathological cardiac fibrosis via PPAR-γ/AKT pathways
Jacobsen et al. Interferon-α2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients: the Norwegian carcinoid study
JP7508496B2 (ja) 心筋症、収縮期心機能不全及びうっ血性心不全症状の治療のためのプロベネシド
CN108738310A (zh) 用于治疗肌营养不良的方法
Zhang et al. Triptolide protects rat heart against pressure overload-induced cardiac fibrosis
JP2001515864A (ja) 非天然ｆｐ選択的作用薬を使用した骨体積増加方法
Dong et al. Polydatin prevents hypertrophy in phenylephrine induced neonatal mouse cardiomyocytes and pressure-overload mouse models
KR20180115297A (ko) Pik3ca-관련된 과성장 스펙트럼(pros-cloves 증후군)의 치료시 사용하기 위한 byl719(알펠리시브)
Xu et al. Ghrelin ameliorates hypoxia-induced pulmonary hypertension via phospho-GSK3 b/b-catenin signaling in neonatal rats
Zhang et al. Chronic GPR30 agonist therapy causes restoration of normal cardiac functional performance in a male mouse model of progressive heart failure: insights into cellular mechanisms
CN109152767A (zh) 用血栓烷-a2受体拮抗剂治疗肌营养不良的组合物和方法
Nawata et al. Dantrolene improves left ventricular diastolic property in mineralcorticoid-salt-induced hypertensive rats
CN101879151A (zh) 大黄素在制备p2x3介导神经病理痛/神经系统疾病药物中的应用
US11752131B2 (en) Methods and pharmaceutical compositions for the treatment of obesity
Xu et al. Ang II enhances atrial fibroblast autophagy and promotes atrial remodeling through the AT1-ERK-mTOR signaling pathway
JP2001515863A (ja) 骨体積増加方法
Zhu et al. TRIF/EGFR signalling mediates angiotensin-II-induced cardiac remodelling in mice
TWI876411B (zh) 治療周邊動脈疾病的用途
Qi et al. Melatonin attenuates cardiac dysfunction and inflammation in dilated cardiomyopathy via M2 macrophage polarization
US20130095059A1 (en) Inhaled no donor kmups derivative preventing allergic pulmonary vascular and bronchial inflammation via suppressed cytokines, inos and inflammatory cell counts in asthma model
McLean et al. PI3K? pathway inhibition with doxorubicin treatment results in distinct biventricular atrophy and remodeling with right ventricular dysfunction
HK40053435A (en) Probenecid for treating decompensated heart failure
Wahlberg The Role of Angiotensin II in Skeletal Muscle Metabolism
CN110604735A (zh) 一种治疗肝纤维化、硬皮病的化合物及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)